Therapeutic Efficacy of Curcumin Nanoparticles in Parkinson's Disease: An Integrated Analysis of Network Pharmacology, Experimental Validation, and Gut Microbiota - PubMed
3 hours ago
- #gut-brain-axis
- #neurodegenerative-disease
- #nanomedicine
- Parkinson's disease (PD) is the second most common neurodegenerative condition globally, with increasing prevalence due to aging populations.
- Curcumin monomers have been shown to alleviate PD symptoms and slow disease progression, but their bioavailability is improved with nano-drug delivery systems.
- Gut microbiota imbalance plays a significant role in PD onset and progression, though the mechanisms of curcumin nanoparticles' therapeutic effects remain unclear.
- Network pharmacology, molecular docking, and molecular dynamics were used to predict and validate curcumin's targets and signaling pathways in PD.
- Curcumin nanoparticles were synthesized using the emulsion-solvent evaporation technique and tested in PD models through behavioral experiments, serological assays, and other methods.
- Results showed curcumin nanoparticles improved motor capabilities, antioxidant enzyme levels, and reduced oxidative stress and neuronal apoptosis via the Akt signaling pathway.
- Histopathological improvements were observed in the hippocampal dentate gyrus (DG) region, and gut microbiota remodeling alleviated neuroinflammation.
- Curcumin nanoparticles activate the Akt signaling pathway to inhibit neuronal apoptosis and remodel gut microbiota, collectively improving PD pathology.
- The study provides pharmacological evidence for curcumin nanoparticles' multi-mechanism therapeutic actions and identifies potential PD treatment targets.